Form 4: Neurocrine Biosciences Executive Julie Cooke Reports Stock Transactions

Chief Human Resources Officer Julie Cooke reports the acquisition and disposal of Neurocrine Biosciences stock and derivative securities, including transactions under 10b5-1 trading plans.

Summary

• Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• The report includes the acquisition of 1,509 shares and 1,401 shares of common stock through the exercise of restricted stock units on February 13, 2025.
• Cooke also disposed of 796 shares and 755 shares of common stock on February 13, 2025, at weighted average prices of $116.7664 and $116.7988, respectively.
• These disposals were executed under Rule 10b5-1 trading plans adopted on March 15, 2023, and June 14, 2024.
• Cooke was granted 29,600 stock options on February 12, 2025, exercisable starting March 12, 2025, and expiring on February 12, 2035.
• She also acquired 5,548 restricted stock units on February 12, 2025, vesting annually starting February 12, 2026.
• Following these transactions, Cooke beneficially owns 20,190 shares of common stock directly and 18,526 shares indirectly through the Cooke Family Trust.
• She also holds 29,600 stock options and 4,203 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and standard executive compensation practices. There is no indication of unusual activity or concern.

Positives

• The granting of stock options and restricted stock units to a key executive could be seen as a positive incentive for future performance.

Negatives

• The sale of shares by a key executive, even under a pre-arranged trading plan, could be interpreted negatively by some investors.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create uncertainty among investors.
• Changes in executive compensation structures, such as the vesting schedules of RSUs, could impact employee retention and motivation.

Future Outlook

The document does not contain specific forward-looking statements, but it outlines the vesting schedule for restricted stock units and the exercisability of stock options, indicating future equity-based compensation for the reporting person.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often related to compensation packages and personal financial planning. Monitoring these transactions can provide insights into executive sentiment and alignment with company performance.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include a mix of salary, stock options, and restricted stock units.
• Vesting schedules for stock options and RSUs typically range from three to five years, aligning with industry norms.
• Rule 10b5-1 trading plans are a common tool used by executives to manage stock sales while avoiding accusations of insider trading, similar to practices at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the executive's stock sales, but the presence of a 10b5-1 plan mitigates concerns about insider trading.
• The granting of stock options and RSUs could positively impact employee morale and retention.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Julie Cooke, Stock Options, Restricted Stock Units, 10b5-1 Trading Plan, Executive Compensation, Beneficial Ownership, Insider Trading